+ Watch STEM
on My Watchlist
A biopharmaceutical company that operates in one segment, the development of novel cell-based therapeutics designed to treat human diseases and disorders.
Government funding and subsidizing. The bill will go through anyday now. Still a buy... lots of money to be made in this industry. This stock had its feet kicked out from under it this morning because of people pocketing profits The sell-off has not real substance. Great time to stock up. The reason these stem cell stocks are so low involves low cash levels, which is a problem but the funding should fix that. All I can say is buy or hold, because the month after Congress passes that bill you will see these reach 10+ and still be rising.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions